Weight-Loss drug trial aims to relieve dangerous brain pressure

NCT ID NCT07191873

Summary

This study is testing whether the medication tirzepatide, which is approved for weight loss and diabetes, can safely reduce high pressure inside the skull for people with idiopathic intracranial hypertension (IIH). The trial will involve 60 adults with IIH and a high body mass index (BMI). Participants will be randomly assigned to receive either tirzepatide or a placebo for 12 months to see if the drug lowers brain pressure and protects vision.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INTRACRANIAL HYPERTENSION (IIH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.